Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KPTI |
---|---|---|
09:32 ET | 15227 | 2.41 |
09:34 ET | 1400 | 2.39 |
09:36 ET | 6874 | 2.365 |
09:38 ET | 12871 | 2.4 |
09:39 ET | 900 | 2.41 |
09:41 ET | 7112 | 2.45 |
09:43 ET | 1900 | 2.45 |
09:45 ET | 3107 | 2.43 |
09:48 ET | 1991 | 2.425 |
09:50 ET | 1086 | 2.405 |
09:52 ET | 500 | 2.4 |
09:54 ET | 7550 | 2.4 |
09:56 ET | 2200 | 2.39 |
09:57 ET | 900 | 2.41 |
09:59 ET | 800 | 2.41 |
10:01 ET | 1400 | 2.41 |
10:03 ET | 1276 | 2.4 |
10:06 ET | 300 | 2.39 |
10:08 ET | 5245 | 2.42 |
10:10 ET | 1700 | 2.42 |
10:12 ET | 2463 | 2.41 |
10:14 ET | 4100 | 2.395 |
10:15 ET | 1200 | 2.41 |
10:17 ET | 2328 | 2.41 |
10:19 ET | 4357 | 2.41 |
10:21 ET | 200 | 2.41 |
10:24 ET | 12900 | 2.405 |
10:26 ET | 8000 | 2.41 |
10:28 ET | 6040 | 2.4 |
10:30 ET | 7179 | 2.405 |
10:32 ET | 11326 | 2.38 |
10:33 ET | 5940 | 2.385 |
10:35 ET | 6400 | 2.39 |
10:37 ET | 5819 | 2.38 |
10:39 ET | 5734 | 2.3825 |
10:42 ET | 17366 | 2.4099 |
10:44 ET | 8794 | 2.385 |
10:46 ET | 4293 | 2.37 |
10:48 ET | 7580 | 2.36 |
10:50 ET | 1925 | 2.365 |
10:51 ET | 1318 | 2.36 |
10:53 ET | 2386 | 2.365 |
10:55 ET | 37631 | 2.375 |
10:57 ET | 1465 | 2.365 |
11:00 ET | 7200 | 2.365 |
11:02 ET | 9935 | 2.365 |
11:04 ET | 1100 | 2.365 |
11:06 ET | 2500 | 2.3625 |
11:08 ET | 8209 | 2.375 |
11:09 ET | 8206 | 2.365 |
11:11 ET | 3785 | 2.355 |
11:13 ET | 14298 | 2.34 |
11:15 ET | 2115 | 2.34 |
11:18 ET | 2170 | 2.34 |
11:20 ET | 3500 | 2.345 |
11:22 ET | 7454 | 2.35 |
11:24 ET | 2829 | 2.36 |
11:26 ET | 5069 | 2.36 |
11:27 ET | 11681 | 2.36 |
11:29 ET | 4564 | 2.35 |
11:31 ET | 300 | 2.35 |
11:33 ET | 1805 | 2.35 |
11:36 ET | 36913 | 2.355 |
11:38 ET | 11049 | 2.34 |
11:40 ET | 3741 | 2.34 |
11:42 ET | 1000 | 2.34 |
11:44 ET | 3100 | 2.35 |
11:45 ET | 1900 | 2.34 |
11:47 ET | 1100 | 2.35 |
11:49 ET | 600 | 2.345 |
11:51 ET | 6083 | 2.335 |
11:54 ET | 8517 | 2.335 |
11:56 ET | 535 | 2.3308 |
11:58 ET | 9714 | 2.325 |
12:00 ET | 800 | 2.325 |
12:02 ET | 1625 | 2.33 |
12:03 ET | 7929 | 2.335 |
12:05 ET | 2670 | 2.3395 |
12:07 ET | 28919 | 2.355 |
12:09 ET | 1909 | 2.355 |
12:12 ET | 100 | 2.355 |
12:14 ET | 3633 | 2.35 |
12:16 ET | 1560 | 2.345 |
12:18 ET | 2659 | 2.34 |
12:20 ET | 700 | 2.34 |
12:21 ET | 500 | 2.34 |
12:23 ET | 801 | 2.34 |
12:25 ET | 1400 | 2.34 |
12:27 ET | 6883 | 2.34 |
12:30 ET | 1300 | 2.34 |
12:32 ET | 12219 | 2.355 |
12:34 ET | 1550 | 2.355 |
12:36 ET | 14403 | 2.345 |
12:38 ET | 16112 | 2.335 |
12:39 ET | 2250 | 2.33 |
12:41 ET | 1343 | 2.34 |
12:43 ET | 800 | 2.33 |
12:45 ET | 700 | 2.335 |
12:48 ET | 700 | 2.33 |
12:50 ET | 1675 | 2.34 |
12:52 ET | 400 | 2.335 |
12:54 ET | 1100 | 2.33 |
12:56 ET | 3893 | 2.325 |
12:57 ET | 647 | 2.32 |
12:59 ET | 700 | 2.32 |
01:01 ET | 54100 | 2.345 |
01:03 ET | 2600 | 2.345 |
01:06 ET | 7455 | 2.35 |
01:08 ET | 739 | 2.345 |
01:10 ET | 187 | 2.348 |
01:12 ET | 900 | 2.3499 |
01:14 ET | 1200 | 2.345 |
01:15 ET | 800 | 2.34 |
01:17 ET | 1800 | 2.345 |
01:19 ET | 1036 | 2.34 |
01:21 ET | 700 | 2.34 |
01:24 ET | 2000 | 2.345 |
01:26 ET | 1500 | 2.345 |
01:28 ET | 5938 | 2.345 |
01:30 ET | 1368 | 2.34 |
01:32 ET | 836 | 2.345 |
01:33 ET | 700 | 2.35 |
01:35 ET | 1450 | 2.345 |
01:37 ET | 8464 | 2.335 |
01:39 ET | 4635 | 2.345 |
01:42 ET | 1878 | 2.34 |
01:44 ET | 3503 | 2.34 |
01:46 ET | 600 | 2.335 |
01:48 ET | 11936 | 2.32 |
01:50 ET | 2583 | 2.33 |
01:51 ET | 1400 | 2.33 |
01:53 ET | 1854 | 2.33 |
01:55 ET | 1600 | 2.33 |
01:57 ET | 1300 | 2.33 |
02:00 ET | 1900 | 2.325 |
02:02 ET | 1610 | 2.325 |
02:04 ET | 400 | 2.325 |
02:06 ET | 5900 | 2.325 |
02:08 ET | 1900 | 2.325 |
02:09 ET | 3272 | 2.325 |
02:11 ET | 1100 | 2.33 |
02:13 ET | 1700 | 2.3225 |
02:15 ET | 32878 | 2.335 |
02:18 ET | 2300 | 2.34 |
02:20 ET | 604 | 2.34 |
02:22 ET | 1648 | 2.34 |
02:24 ET | 1297 | 2.335 |
02:26 ET | 8252 | 2.345 |
02:27 ET | 4800 | 2.345 |
02:29 ET | 200 | 2.35 |
02:31 ET | 1200 | 2.345 |
02:33 ET | 300 | 2.35 |
02:36 ET | 900 | 2.345 |
02:38 ET | 2000 | 2.345 |
02:40 ET | 600 | 2.3425 |
02:42 ET | 1300 | 2.345 |
02:44 ET | 1530 | 2.3425 |
02:45 ET | 12525 | 2.355 |
02:47 ET | 8477 | 2.345 |
02:49 ET | 200 | 2.345 |
02:51 ET | 1600 | 2.345 |
02:54 ET | 939 | 2.345 |
02:56 ET | 500 | 2.345 |
02:58 ET | 5227 | 2.3495 |
03:00 ET | 700 | 2.345 |
03:02 ET | 2787 | 2.35 |
03:03 ET | 18230 | 2.36 |
03:05 ET | 5038 | 2.345 |
03:07 ET | 1744 | 2.345 |
03:09 ET | 900 | 2.345 |
03:12 ET | 1200 | 2.34 |
03:14 ET | 9157 | 2.335 |
03:16 ET | 8629 | 2.345 |
03:18 ET | 900 | 2.345 |
03:20 ET | 400 | 2.345 |
03:21 ET | 6165 | 2.345 |
03:23 ET | 2197 | 2.35 |
03:25 ET | 6320 | 2.3325 |
03:27 ET | 10298 | 2.34 |
03:30 ET | 3139 | 2.335 |
03:32 ET | 9071 | 2.335 |
03:34 ET | 17218 | 2.325 |
03:36 ET | 15477 | 2.325 |
03:38 ET | 7638 | 2.325 |
03:39 ET | 8401 | 2.32 |
03:41 ET | 4212 | 2.325 |
03:43 ET | 2318 | 2.325 |
03:45 ET | 2998 | 2.325 |
03:48 ET | 3975 | 2.325 |
03:50 ET | 26646 | 2.335 |
03:52 ET | 16557 | 2.325 |
03:54 ET | 12900 | 2.325 |
03:56 ET | 13100 | 2.32 |
03:57 ET | 26201 | 2.325 |
03:59 ET | 352533 | 2.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Karyopharm Therapeutics Inc | 264.5M | -1.3x | --- |
MacroGenics Inc | 315.4M | -3.4x | --- |
Kamada Ltd | 237.9M | -102.3x | --- |
Anika Therapeutics Inc | 403.9M | -18.0x | --- |
Poseida Therapeutics Inc | 206.5M | -2.2x | --- |
Codexis Inc | 164.9M | -3.4x | --- |
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is evaluating eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $264.5M |
---|---|
Revenue (TTM) | $148.1M |
Shares Outstanding | 114.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.03 |
EPS | $-1.80 |
Book Value | $-0.15 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -93.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.